Imperva Data Security Fabric Provides Bold New Approach to Securing All Data in Multicloud and Hybrid Environments
5.4.2022 15:00:00 EEST | Business Wire | Press release
Imperva, Inc., (@Imperva) the comprehensive digital security leader, introduces the Imperva Data Security Fabric (DSF) to modernize and simplify data governance, security, and workflow management for all data across multicloud and hybrid environments. Imperva DSF standardizes data security controls across enterprise environments to provide full visibility of what is happening across all file stores and assets, on-premises, and across clouds. Its flexible architecture supports a wide range of data repositories, ensuring security policies are applied consistently everywhere.
Imperva DSF integrates Imperva Sonar and a deep portfolio of industry-leading and mission critical Imperva Data Security products and technologies. Customers are already using Imperva DSF capabilities to secure data in hundreds of data stores across leading cloud providers. These capabilities provide access to thousands of automation and response integrations to streamline visibility, create specific rules for managing data risk, and leverage a mix of security tools supporting those platforms.
Imperva DSF makes it easier for customers to understand and mitigate data risk at every step of their security journey across structured, semi-structured, and unstructured data. According to Gartner, “by 2024, larger enterprises will triple the unstructured data stored as file or object storage on-premises, at the edge or in the public cloud, compared with 2020. This massive growth in unstructured data demands better protection against threats such as ransomware.1” Imperva DSF can discover and classify more than 350 unique file formats, including the most widely used formats by Adobe, Google, Microsoft, and many others. Imperva DSF protects a customer’s multicloud and hybrid environments and provides visibility through a single service that can run anywhere within that environment. Imperva DSF provides a holistic view that makes it easier for customers to quickly identify and secure sensitive information across their entire protected environment.
Across a broad range of areas including policy compliance, compromised credentials, unintentional misuse, and malicious threats to sensitive data, organizations in all industries around the world are asking for our help to protect their data. They need broad but centralized control and automation for a more comprehensive view of risk posture, faster insights to accelerate response times, and reduced cost of ownership,” says Dan Neault, SVP and GM, Data Security, Imperva. “Imperva Data Security Fabric enables organizations to safeguard their sensitive data while ensuring data security, compliance, and privacy, and managing digital risk while confidently moving strategic data to the cloud.”
Imperva DSF and its unique automation capabilities for agent and agentless deployments makes it simpler and lower cost for customers to scale data governance and protection anywhere. "After going through a painful situation with another Data Activity Monitoring solution, we went with Imperva because we needed to deliver something quickly for compliance reasons. Imperva offered us a more efficient agent-based solution in terms of cost, management and a lot less complexity. You get to do everything in a single place,” says Diego Laverde, CISO of Banco Popular Dominicano. “It went into production seamlessly, the business didn’t even realize that it had happened, and it worked as it should.”
Through the Imperva Technology Alliance Program (TAP), Imperva DSF has built-in integrations with the world’s leading hyperscalers (e.g., Amazon Web Services™, Microsoft® Azure®, Google Cloud™, etc.), database vendors (e.g., Microsoft®, MongoDB® Atlas, Oracle DBMS, Snowflake™, etc.), and workflow managers (e.g., Atlassian, ServiceNow™, etc.). Imperva DSF opens up new partner-builder innovation opportunities to provide customers additional capabilities and simplify their orchestration. Imperva TAP is pleased to welcome Mage™ (formerly Mentis), a data masking alternative to Imperva DSF built-in capabilities to help customers secure structured and unstructured data throughout the development lifecycle.
“We are excited about the possibilities Imperva DSF enables for mutual customers and the partner ecosystem,” says Rajesh Parthasarathy, CEO of Mage. “Our technology alliance with Imperva provides organizations with an analyst-recognized integrated masking solution for all data types supported by the Imperva DSF.”
Imperva Data Security Fabric includes:
- Data Activity Monitoring: mitigate malicious insiders and external threats by detecting changes, auditing activities for compliance, and blocking or alerting on policy violations.
- Data Risk Analytics: automate detection of non-compliant, risky, or malicious data access behavior across data stores.
- Data Governance: discover and classify sensitive data residing in structured, semi-structured, and unstructured data types, to operationalize security control policies.
- Data Access Control: control user rights to sensitive data, including detecting overly-broad data access in the cloud or on-premises.
- Data Masking: transform data so it is either unreadable or de-identified, allowing processing to happen in compliance.
Additional Information:
- Learn more about the Imperva Technology Alliance Partner Program and apply to join
- Watch the explainer video Imperva Data Security Fabric
- Explore Imperva Data Security
- Check out the Imperva Blog for the latest products and solutions news, and threat intelligence from Imperva Threat Research
GARTNER is registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved
About Imperva
Imperva is the comprehensive digital security leader on a mission to help organizations protect their data and all paths to it. Only Imperva protects all digital experiences, from business logic to APIs, microservices, and the data layer, and from vulnerable, legacy environments to cloud-first organizations. Customers around the world trust Imperva to protect their applications, data, and websites from cyber attacks. With an integrated approach combining edge, application security, and data security, Imperva protects companies ranging from cloud-native start-ups to global multi-nationals with hybrid infrastructure. Imperva Threat Research and our global intelligence community keep Imperva ahead of the threat landscape and seamlessly integrate the latest security, privacy, and compliance expertise into our solutions.
© 2022 Imperva, Inc. All rights reserved. Imperva is a registered trademark of Imperva, Inc.
1Gartner Hype Cycle for Storage and Data Protection Technologies, Julie Palmer, 22 July 2021
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005023/en/
Contact information
Erik Kingham
erik.kingham@imperva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
